Navigation Links
Delcath to Present at Upcoming Investor Conferences
Date:3/2/2011

NEW YORK, March 2, 2011 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that executive management will present an overview of the Company's business strategy and recent corporate developments at the following investor conferences:

  • The Cowen and Company Healthcare Conference in Boston.  Mr. Eamonn Hobbs, Chief Executive Officer, and Mr. David McDonald, Chief Financial Officer, are scheduled to present an overview of the Company on Tuesday, March 8, 2011 at 10:15 a.m. ET.
  • ROTH Capital Annual OC Growth Stock Conference in Laguna Niguel, California.  Mr. Hobbs is scheduled to present an overview of the Company on Monday, March 14, 2011 at 1:30 p.m. PT.

  • Attendance at each of these conferences is by invitation only. Delcath will offer live and audio webcasts of its presentation, which may be accessed on the Investor Relations section of the Company's website at www.delcath.com.  An archived replay of the presentations will be available for 90 days, also at www.delcath.com.

    About Delcath SystemsDelcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

    Media Contact:Gregory Gin/Doug Sherk

    Janine McCargoEVC Group

    EVC Group646-445-4801/415-896-6818

    646-688-0425
    '/>"/>

    SOURCE Delcath Systems, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Delcath Systems Receives Refusal to File Letter From FDA
    2. Delcath Achieves ISO 13485 Certification
    3. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
    4. Delcath Systems Announces Third Quarter Progress Report Conference Call
    5. Delcath Strengthens Research and Development Team with Key Appointments
    6. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
    7. Delcath to Present at the William Blair Emerging Growth Stock Conference
    8. Delcath to Present at the JMP Securities Healthcare Conference
    9. Delcath Systems Announces Completion of Common Stock Offering
    10. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
    11. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
    (Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
    (Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
    Breaking Medicine Technology:
    (Date:9/25/2017)... ... September 25, 2017 , ... ... excited to announce the next generation for LASIK in Manhattan with Contoura Vision, ... most technologically advanced laser systems available in the United States to correct nearsightedness ...
    (Date:9/25/2017)... ... September 25, 2017 , ... ... Community”: a gripping look at the religious stand in the sensitive matter ... love and compassion. “The Ministry of Reconciliation: A Compassionate and Realistic Approach to ...
    (Date:9/25/2017)... ... ... The trend-spotters, tastemakers, and healthy lifestyle product experts at the New ... with the new NEXTY Gold Award at the Natural Products Expo East trade show ... is reserved for just those companies that hit high marks on the criteria of ...
    (Date:9/25/2017)... ... September 25, 2017 , ... ... September 28, 2017 to deliver a powerful message of teamwork, unity and collaboration ... Feature film writer/director Robert Adetuyi (Beat the World, Stomp the Yard) and Grammy-nominated ...
    (Date:9/24/2017)... Michigan (PRWEB) , ... September 23, 2017 , ... Throughout ... do no harm. , Every day, physicians, nurses and other providers work to ... treatments and innovative industry processes. , But U.S. Senators today are threatening to ...
    Breaking Medicine News(10 mins):